| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lake Street analyst Frank Takkinen maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $8 to $4.
D. Boral Capital analyst Jason Kolbert maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $14.
Preliminary, Unaudited Third Quarter 2025 RevenueTotal worldwide revenue for the third quarter of 2025 is anticipated to be app...